YOLFTbeta
Tissue Repair Ltd

Tissue Repair Ltd

TRP · AU · Healthcare / Biotechnology

0.11AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.11
Open0.11
Day Range0.11 – 0.11
52-Week Range0.055 – 0.48
Volume21.74K
Market Cap5.14M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.08
Dividend Yield0.00%
Beta0.22
50-Day Avg0.0852
200-Day Avg0.1502

About

Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and aesthetic procedure aftercare in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It also develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures. Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Tony Charara
  • Employees0
  • HeadquartersTower A, The Zenith, Chatswood, NSW, Australia, 2067, Australia
  • Websitehttps://tissuerepair.com.au

Leadership

  • Mr. Tony ChararaCo-Founder, CEO & Executive Director
  • Mr. Peter D. A. Scutt BComCo-Founder & Executive Director
  • Mr. Mark Wouter BouwChief Financial Officer
  • Dr. Sarika NamjoshiChief Operating Officer
  • Ms. Sushma KejriwalCompany Secretary

Financials

Income Statement

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue0156152.64K171.92K3.08K152.24K2.63M559.70K
Growth (%)--+97743.59%+12.63%-98.21%+4849.28%+1629.70%-78.75%
Cost of Revenue---1.71K2.65K1.73K-2.36M
Gross Profit-156152.64K170.21K428150.51K2.63M-1.80M
Gross Margin-100.00%100.00%99.00%13.91%98.86%100.00%-322.23%
Operating Expense-448.88K792.34K4.40M5.74M6.67M7.35M6.17M
Operating Income-557.22K-448.72K-639.70K-4.23M-5.74M-6.52M-4.72M-7.98M
Operating Margin--287641.03%-419.10%-2457.84%-186616.71%-4280.28%-179.30%-1425.03%
EBITDA--52.19K-189.44K-7.01M-5.14M-6.51M-4.72M-7.98M
EBITDA Margin--33455.13%-124.11%-4076.17%-167111.41%-4279.15%-179.30%-1425.03%
Net Income-357.19K-352.21K-915.23K-6.84M-4.17M-4.14M-4.24M-5.36M
Net Income Margin--225778.21%-599.61%-3977.17%-135709.14%-2718.15%-160.96%-958.01%
R&D-325.07K354.14K1.42M2.61M3.24M4.04M4.86M
R&D as % of Total Revenue-208381.41%232.01%826.66%84920.61%2125.82%153.52%869.19%
Interest Expense-120389.89K3----
Interest Expense % of Total Revenue-76.92%255.44%0.00%----

Balance Sheet

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.33M27.61M25.90M22.38M19.39M14.57M10.34M
Total Liabilities329.11K536.00K559.64K497.35K1.35M662.53K1.57M
Total Equity999.90K27.07M25.34M21.88M18.04M13.91M8.77M
Cash1.15M27.11M25.46M21.40M16.44M12.32M4.77M
Total Debt-7.50M-----
Net Debt-1.15M-19.61M-25.46M-21.40M-16.44M-12.32M-4.77M

Cash Flow

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-649.98K-852.89K-3.97M-4.26M-4.95M-3.70M-7.50M
Investing Cash Flow5.00K5.00K-3.92K-2.24K-3.35K-421.67K-43.65K
Financing Cash Flow1.20M7.46M21.36M0000
Capital Expenditure3.92K3.92K3.92K2.24K3.35K421.67K43.64K
Free Cash Flow-649.98K-852.89K-3.97M-4.26M-4.95M-4.12M-7.55M
FCF to OCF100.00%100.00%100.10%100.05%100.07%111.40%100.58%

Earnings

Report DateFeb 24, 2022Aug 31, 2022Feb 22, 2023Feb 27, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.00
EPS Actual-0.13-0.03-0.05-0.04-0.03
Surprise-----
Timing--After-hours--

Key Statistics & Ratios

Market Cap5.14M
Enterprise Value671.08K
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.72
Price / Book0.62
EPS-0.08
Book Value0.145
Revenue (TTM)2.99M
Gross Profit (TTM)2.77M
EBITDA-5.32M
Profit Margin-179.28%
Operating Margin-204.77%
Return on Equity-47.27%
Return on Assets-27.82%
Shares Outstanding60.46M
Shares Float34.36M
Beta0.22
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%